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Abstract:  
Introduction: The underlying problem for two 
of the three most common patterns of 
unexpected hospital deaths (PUHD) is 
hypoventilation1. Concern over this opioid-
induced respiratory depression has led many 
experts and consensus guidelines to 
recommend that all patients receiving 
opioids be monitored for respiratory rate. 
Currently, no clinically accepted “gold-
standard” monitoring device exists for non-
intubated, spontaneously breathing patients. 
We studied seven distinct respiratory 
sensors to compare their effectiveness in 
respiratory monitoring.  Methods: With IRB 
approval, data were collected from 26 
volunteers who were administered target 
controlled infusions of remifentanil and 
propofol in order to induce low respiratory 
rates. Data were collected from a suite of 
sensors which were analyzed using a single, 
custom breath detection algorithm.  Breath 
rates derived from a capnometer, 
accelerometer, oro-nasal thermistor, nasal 
pressure transducer, microphone, 
photoplethysmogram, and impedance 
respiratory sensor were compared against 
breath rates derived from the reference 
standard of respiratory inductance 
plethysmography bands at both low and 
normal respiratory rate ranges.  Results: 
Capnometry and acceleromtry reported 
respiratory rates closest to those reported by 
the respiratory inductance plethysmography 
bands. Conclusion: Detecting respiratory 
rate in the post-operative environment is a 
clinically challenging problem which likely 
requires further study.  
 
INTRODUCTION & BACKGROUND 
The underlying problem for two of the three 
most common patterns of unexpected 
hospital deaths (PUHD) is hypoventilation1. 
Type II PUHD (CO2 narcosis) involves a 
reduction in respiratory rate and/or tidal 
volume, and if supplemental oxygen is being 
provided, a pulse oximeter will not detect the 
problem until the hypercarbia is significantly 
advanced and the patient is near respiratory 
arrest. Type III PUHD is induced by 
obstructive sleep apnea in the presence of 
arousal failure, and is recognized as a 
repetitive sequence of cyclic apneas and 
self-arousals which precede the final apnea. 
A pulse oximeter alarms with each apneic 
period and will likely be interpreted as 
generating many false positive alarms.1 The 
risk of opioid-induced respiratory depression 
in postoperative patients is greatest in the 
first 24 hours after initiation of opioids2, and 
opioids are the most commonly used drug for 
treating pain in the postoperative period.3 
These problems would be especially 
troublesome during long-range, manned 
space missions where monitoring personnel 
are limited due to either sedation of crew 
members or an injury rendering the crew 
short-handed. 
Respiratory depression is caused by drug-
induced inhibition of the breathing control 
center of the brain stem. Partial to full airway 
obstruction is an anatomic problem involving 
the soft palate, tongue base, and/or 
epiglottis, caused by drug-induced 
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decreases in airway patency and muscle 
tone. Sedatives and opioids depress the 
response to elevated CO2 (reduced drive to 
breathe), worsen arousal, cause airway 
obstruction, and change sleep patterns4-8 
In the postoperative period, most adverse 
respiratory events occur during the first 24 
hours of opioid administration.2 During this 
period, pulse oximeter monitoring, 
supplemental oxygen, incentive spirometry, 
and intermittent nursing observation are the 
primary interventions used to fend off 
adverse respiratory events. For inpatient 
monitoring, pulse oximetry is often 
inadequate. On a busy hospital floor, it is 
difficult to respond to multiple remote 
advisory pulse oximetry alarms. Pulse 
oximeter alarms are ignored because they 
have a high false-positive alarm rate due to 
movement artifact and displacement.9,10 
Pulse oximetry primarily monitors 
oxygenation instead of ventilation; the SpO2 
signal is a delayed indicator for apnea or 
hypopnea, particularly when supplemental 
oxygen is given. By the time the pulse 
oximeter alarms, an apneic patient is already 
in danger of hypoxia, brain injury and death. 
Despite exhaustive studying of respiratory 
monitoring technologies, no sensor has 
emerged as a clinically accepted gold-
standard for non-intubated, spontaneously 
breathing patients11. Monitors which are 
currently used elsewhere in the healthcare 
environment may not be suited to this 
situation. Capnometry, often used during 
intubations, relies on an adequate gas 
sample from the airway which may be difficult 
to obtain in the non-intubated environment. 
Pulse oximetry is notoriously delayed in 
detecting apnea, especially when patients 
are receiving supplemental oxygen. In 
addition, neither of these monitoring 
modalities distinguish between central apnea 
and obstructive apnea, which may influence 
clinical decision making.  
We suggest that there is an urgent need for 
a low cost, reliable respiratory depression 
monitoring technique that can be integrated 
with the signals from the pulse oximeter to 
give additional physiologic information about 
a patient’s sufficiency of both ventilation and 
oxygenation in the non-intubated setting. 
Currently, we are exploring the value of 
integrating the information from a set of low-
cost physiologic monitors to detect 
respiratory rate. Specifically, we studied a 
capnometer, accelerometer, nasal pressure 
transducer, thermistor, peri-tracheal 
microphone, photoplethysmogram, chest 
impedance, and respiratory inductance 
plethysmography.  
We tested each sensor under identical 
conditions in order to reduce as many 
variables as possible in the comparison. 
Specifically, each sensor recorded data from 
the same subjects, and during the same time 
period. An identical, threshold-based breath 
detection algorithm was then implemented 
on each signal in order to detect breathing. 
The goal was to establish the comparative 
strengths and weaknesses of each sensor in 
different respiratory rate ranges.  
METHODS 
Informed written consent was obtained from 
26 volunteers (13 male, 13 female).  Eligible 
volunteers had an ASA physical status of I or 
II, age 18 to 55 years, body mass index 
between 18 and 30 kg/m2, negative drug 
screen, and uncomplicated airway anatomy. 
Volunteers were not eligible if they had a 
history of significant alcohol or drug abuse, a 
positive drug-screening test, allergy to 
opioids or propofol, obstructive sleep apnea, 
any prescription medication intake other than 
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oral contraceptives in the 48 hours preceding 
the study, or medical illnesses that are 
known to alter the pharmacokinetics or 
pharmacodynamics of opioids or intravenous 
anesthetics. 
Volunteer subjects were instrumented with a 
three lead electrocardiogram that detects 
respiratory rate using chest impedance 
(Datex Ohmeda, GE Healthcare, Helsinki, 
Finland), a photo-plethysmography (PPG) 
sensor (SET, Masimo Corporation, Irvine, 
CA), an abdominal accelerometer sensor 
(ADXL345, Analog Devices, Norwood, MA),  
respiratory inductance plethysmography 
(RIP) chest bands (Q-RIP, Braebon Medical 
Corporation, Kanata, ON, Canada), a 
capnometer nasal cannula (LoFlo, Philips 
Medical, Wallingford CT), a nasal airway 
pressure sensor (1 INCH-D-4V, All Sensors, 
Morgan Hill, CA), a nasal/oral thermistor 
(Disposable Adult Airflow Sensor, Braebon 
Medical Corporation, Kanata, ON, Canada), 
and a peri-tracheal microphone (Audio-
Technica ATR3350iS. Machida, Tokio, 
Japan) positioned within a metal pre-cordial 
stethoscope cup (Wenger #00-390-c, AINcA, 
San Marcos, CA) placed just below the 
larynx and above the suprasternal notch. 
Data waveforms were digitized at 100 Hz 
with the exception of the acoustic waveform 
which was digitized at 44.1 kHz.    
A 20 gauge venous catheter was placed in 
an antecubital vein under local anesthesia 
(0.2 mL of 0.5% lidocaine) for the purpose of 
hydration and drug administration.  The IV 
site was similar in all subjects. A 
maintenance infusion of 0.9% sodium 
chloride was administered at 1 ml/kg/hour 
throughout the study. Continuous infusions 
of Remifentanil and Propofol was infused 
into this peripheral IV.  
Our team previously characterized various 
effects of sedatives combined with opioids 
using drug interaction models. Specifically, 
we characterized the interaction of Propofol 
and Remifentanil on metrics of airway 
obstruction and intolerable ventilatory 
depression in volunteers.8 Each subject 
received Propofol and Remifentanil. Similar 
to previously collected data from our 
volunteer laboratory (Kern et al, 2004), each 
drug was administered using a computer 
controlled (Stanpump14) continuous infusion 
pump (Pump 22; Harvard Apparatus, 
Limited, Holliston, MA) to achieve selected 
target effect site concentrations.  The effect 
site concentration refers to the drug 
concentration at the pharmacologic site of 
action. Pharmacokinetic parameters 
published by Minto et al.15 and Schnider et 
al.16 was used for Remifentanil and Propofol 
respectively. 
We administered Propofol and Remifentanil 
pairs in a dose escalation scheme with small 
steps in order to creep up to the desired 
target effects of respiratory depression, 
airway obstruction and both effects while 
avoiding overshoot. To accomplish this, the 
Propofol was dosed in a range of 0.75 - 4 
mcg/mL in dose escalation steps of 
approximately 0.5 mcg/mL. Remifentanil was 
dosed in a range of 0.75 to 4.0 ng/mL in 
escalation steps of approximately 0.25-0.5 
ng/mL.  
Data were isolated from periods during which 
the patient was unperturbed, not talking, and 
breathing normally (no obstruction present). 
Samples of all acquired waveforms and the 
filteres used to process them are shown in 
Figure 1.  
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Figure 1: Raw signal waveforms before and after filtering. Filters used are indicated on the transitional arrows. 
PPG indicates photoplethysmography. 
2018 Rocky Mountain Space Grant Consortium                                                                                                                     5 
 
A custom algorithm which detects peak 
prominence in each signal and compares it 
to predefined thresholds was used to detect 
breathing in each signal. Respiratory rate 
during each acquired minute of data was 
calculated for each sensor and compared to 
the reference standard of respiratory 
inductance plethysmography.  
A Bland-Altman style analysis was 
performed on two sets of data. In one set, all 
respiratory rate ranges were included. In the 
second set, only data where the reference 
respiratory rate was 10 or fewer breaths per 
minute was used. In these analyses, bias is 
calculated as the mean difference in the 
respiratory rates reported by the reference 
and comparison sensor signals (reference 
minus comparison). Standard deviation is 
the square root of the statistical variance that 
assumes a normal distribution. A 95% 
confidence interval is calculated as bias ± 
standard deviation. A sample Bland-Altman 
style plot is presented in figure 2. 
 
RESULTS 
A total of 877 minutes of data fit the criteria 
described in the methods. The results of the 
Bland-Altman analysis which includes all 
respiratory rates is presented in Table 1. The 
accelerometer, nasal pressure, thermistor, 
and capnometer all exhibited low bias (<.4 
BPM). Impedance, photoplethysmogram, 
and microphone all exhibited relatively high 
bias (1.4-2 BPM). The signals with the lowest 
standard deviation were the accelerometer 
and the capnometer. The highest standard 
deviations were exhibited by the respiratory 
impedance, photoplethysmogram, and 
microphone. 
A total 407 minutes were available where the 
reference signal reported a respiratory rate 
of 10 or fewer breaths per minute. The 
results of the Bland-Altman analysis on this 
data set is presented in Table 2.  All signals 
exhibited low bias (-.6 BPM). The signals 
with the lowest standard deviation were the 
accelerometer and capnometer.  
CONCLUSION 
A low cost, accurate, and minimally sized 
respiratory monitor would be useful during 
space travel when personnel are limited 
following an injury/emergency procedure or if 
astronauts were to be sedated during 
extended voyages.  
Overall, obtaining accurate respiratory rates 
in non-intubated, spontaneously breathing 
volunteers is challenging. We were able to 
obtain reasonably reliable respiratory rates 
from two signals—an accelerometer and 
capnometer. These signals generally 
exhibited the lowest signal-to-noise ratio and 
lowest amount of signal drop-out. The 
impedance primarily struggled with a low 
signal-to-noise ratio that stemmed from 
cardiogenic motion. The thermistor primarily  
Figure 2: Blant-Altman style plot comparing capnometry 
against Respiratory Inductance Plethysmography at 
respiratory rate of 10 or fewer breaths per minute. 
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struggled with high sensitivity to external 
airflows. In the case of the microphone and 
the photoplethysmogram, the filtering 
method was a concern. Both signals have 
much higher underlying frequencies (sound 
and heart rate) that had to be filtered out 
using an envelope filtering technique. This 
method may have been imperfect for 
assessing respiratory rate in these signals.  
There were many other limitations to 
consider when analyzing these results. All  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
data was collected from healthy volunteers 
who instructed to lay quietly. This may not  
reflect the clinical condition. Additionally, 
subjects were receiving 2 L/min of oxygen 
through a nasal cannula which may have had 
an effect on the nasal pressure, thermistor, 
and capnometer signals. Additionally, the 
algorithm may not be as suited to some 
signal waveforms as others (as noted in the 
case of the photoplethysmogram and 
microphone).  
 Accelerometer 
Nasal 
Pressure 
Thermistor Impedance Capnometer PPG Microphone 
Bias (BPM) 
-0.30 -0.40 -0.20 -1.40 0.00 -2.00 -1.70 
Std (BPM) 
1.89 2.76 2.34 4.95 1.25 4.87 4.52 
Upper 95% 
Confidence 
Interval (BPM) 
3.40 5.00 4.40 8.30 2.50 7.50 7.20 
Lower 95% 
Confidence 
Interval (BPM) 
-4.00 -5.80 -4.80 -11.10 -2.50 -11.50 -10.60 
 Accelerometer 
Nasal 
Pressure 
Thermistor Impedance Capnometer PPG Microphone 
Bias (BPM) 
0.10 0.00 0.50 0.60 0.20 0.40 0.20 
Std (BPM) 
1.08 2.49 2.07 3.92 1.17 3.03 2.15 
Upper 95% 
Confidence 
Interval (BPM) 
2.20 4.90 4.60 8.30 2.50 6.30 4.40 
Lower 95% 
Confidence 
Interval (BPM) 
-2.00 -4.90 -3.60 -7.10 -2.10 -5.50 -4.00 
Table 1: Bland-Altman summary statistics for all sensors and all respiratory rate ranges. PPG 
indicates photoplethysmography.  
Table 2: Bland-Altman summary statistics for all sensors and low respiratory rate ranges (10 or 
fewer breaths per minute as detected by the reference signal). PPG indicates 
photoplethysmography.  
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The comparison in signal performance 
between high and low respiratory rates may 
help influence decision making when 
choosing a sensor to monitor patients who 
are at risk of developing respiratory 
complications. All signals improved when 
monitoring for low respiratory rates, however 
the accelerometer had the highest relative 
improvement, indicating it may be especially 
suited to detecting these clinical conditions.  
We intend to continue this analysis and 
analyze how each signal performs in 
detecting specific clinical pathologies. 
Additionally we will study whether accuracy 
can be improved through sensor fusion 
techniques.  
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